VivoSim Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
VivoSim Labs, Inc. (VIVS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.31 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-06-30 was $1.31, a 32.12% decline year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-06-30 was $1.93, a 94.95% increase year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-06-30 was $0.99, a 45.30% decline year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-06-30 was $1.81, a 37.80% decline year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $2.05, a 71.17% decline from fiscal 2025.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $7.11, a 325.75% increase from fiscal 2024.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.67, a 28.63% decline from fiscal 2023.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.34, a 61.26% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.31 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $2.05 10-K · filed 2026-07-14 | |||
| 2025-12-31 | $2.01 10-Q · filed 2026-02-11 | |||
| 2025-09-30 | $1.81 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.93 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $7.11 10-K · filed 2025-06-05 | |||
| 2024-12-31 | $0.59 10-Q · filed 2025-02-19 | |||
| 2024-09-30 | $0.59 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | $0.99 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $1.67 10-K · filed 2024-05-31 | |||
| 2023-12-31 | $1.72 10-Q · filed 2024-02-08 | |||
| 2023-09-30 | $1.81 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.81 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $2.34 10-K · filed 2023-07-14 | |||
| 2022-12-31 | $2.51 10-Q · filed 2023-02-09 | |||
| 2022-09-30 | $2.56 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $2.91 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $6.04 10-K · filed 2022-06-10 | |||
| 2021-12-31 | $6.65 10-Q · filed 2022-02-14 | |||
| 2021-09-30 | $7.66 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $8.48 10-K · filed 2021-06-15 | |||
| 2020-12-31 | $7.59 10-Q · filed 2021-02-08 | |||
| 2020-09-30 | $7.61 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $0.32 10-K · filed 2020-05-28 | |||
| 2019-12-31 | $0.32 10-Q · filed 2020-02-10 | |||
| 2019-09-30 | $0.32 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $1.29 10-K · filed 2019-06-03 | |||
| 2018-12-31 | $1.29 10-Q · filed 2019-02-07 | |||
| 2018-09-30 | $1.29 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $1.84 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $2.64 10-K · filed 2018-05-31 | |||
| 2017-12-31 | $2.64 10-Q · filed 2018-02-08 | |||
| 2017-09-30 | $2.65 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $2.73 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $3.79 10-K · filed 2017-06-07 | |||
| 2016-12-31 | $3.82 10-Q · filed 2017-02-09 | |||
| 2016-09-30 | $3.85 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $3.21 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $3.87 10-K · filed 2016-06-09 | |||
| 2015-12-31 | $4.08 10-Q · filed 2016-02-08 | |||
| 2015-09-30 | $4.13 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $4.92 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $6.18 10-K · filed 2016-06-09 | |||
| 2014-12-31 | $7.23 10-Q · filed 2015-02-06 | |||
| 2014-09-30 | $7.53 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $7.31 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $8.63 10-K · filed 2015-06-09 | |||
| 2013-12-31 | $5.32 10-Q · filed 2014-02-06 | |||
| 2013-09-30 | $5.09 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $4.15 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $3.93 10-K · filed 2014-06-10 | |||
| 2012-12-31 | $1.95 10-K · filed 2014-06-10 | |||
| 2012-09-30 | $1.82 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | $2.25 10-Q · filed 2012-08-14 | |||
| 2011-12-31 | $0.08 10-K · filed 2014-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |